BiotechTube

Remibrutinib oral treatment + Ocrelizumab

Phase 3Recruiting
0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing Multiple Sclerosis

Conditions

Relapsing Multiple Sclerosis

Trial Timeline

Jul 23, 2025 → Jun 20, 2031

NCT ID
NCT06846281

About Remibrutinib oral treatment + Ocrelizumab

Remibrutinib oral treatment + Ocrelizumab is a phase 3 stage product being developed by Novartis for Relapsing Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06846281. Target conditions include Relapsing Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing Multiple Sclerosis were approved

Approved (20) Terminated (2) Active (0)
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved
✅Interferon beta-1aMerckApproved
✅Cladribine 10 mg oral tabletMerckApproved
✅Rebif® (clone 484-39)MerckApproved
✅RebifMerckApproved
✅Fingolimod 0.5 mgNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06846281Phase 3Recruiting

Competing Products

20 competing products in Relapsing Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
Placebo + PirtobrutinibEli LillyPhase 2
27
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
dirucotide + placeboEli LillyPhase 2/3
38
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRNMerckPhase 3
40
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Teriflunomide + EvobrutinibMerckPhase 3
32
Cladribine + Placebo + Microgynon®MerckPhase 1
29